Skip to main content
Clinical Trials/ACTRN12612000765820
ACTRN12612000765820
Recruiting
Phase 3

In critically ill patients with acute kidney injury does continuous renal replacement therapy (CRRT) using a machine controlled citrate protocol compared to a regional heparin protcocol improve safety and extend filter life.

Dr. Matthew Brain0 sites200 target enrollmentJuly 18, 2012

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
Acute Kidney Injury
Sponsor
Dr. Matthew Brain
Enrollment
200
Status
Recruiting
Last Updated
6 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
July 18, 2012
End Date
TBD
Last Updated
6 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
Dr. Matthew Brain

Eligibility Criteria

Inclusion Criteria

  • Greater than 18 years old
  • Diagnosis of acute renal failure with an indication for renal replacement therapy as assessed by one or more of the following criteria:Oliguria (urine output \< 100ml in a 6hour period) unresponsive to fluid resuscitation;volume overload, not correctable by diuretics in spite of adequate blood pressure and creatinine \> 100umol.L; increase of serum creatinine \> 300 umol/L or BUN \> 25mmol/L;increase of serum potassium \> 6\.5 mmol/L due to AKI

Exclusion Criteria

  • Patient weight \< 30kg (determined by machine specification)
  • Inability to enter randomization due to a contraindication to one of the treatment arms:
  • Indication for systemic anticoagulation with heparin (therapeutic range APTT) or an equivalent therapeutic dose of low molecular weight heparin (note this does not include routine thromboprophylaxis with these agents)
  • Prior development of HIT
  • History of anaphylaxis to heparin, protamine or citrate.
  • Pregnancy, or lactation.
  • Patients on chronic renal replacement therapy prior to ICU presentation.
  • Indication for therapeutic hypothermia
  • Previous participation in the same study
  • Indication for a filter set other than the AN69 ST100 1m2 set or a specific dialysis prescription differing from the study protocol (as deemed by the treating physician)

Outcomes

Primary Outcomes

Not specified

Similar Trials